Biomaterial-based Treatments for Ocular Conditions
Synakis is a pre-clinical biotech startup developing novel biomaterial-based treatments for ocular injuries and diseases, including retinal detachment and glaucoma. Our mission is to restore vision and improve the lives of patients suffering from these conditions.
Synakis’ core technology, SNK-125, is a novel hydrogel specifically designed for ocular delivery. SNK-125 is injectable, biocompatible, biodegradable, non-swelling and transparent. We are developing it as a vitreous substitute for vitreoretinal surgery and to deliver engineered therapeutics to treat leading causes of blindness.
Upcoming Events
Want to learn more about Synakis or meet our team? Catch us at these exciting upcoming events!